Atea Pharmaceuticals, Inc. (AVIR)

3,8500 +0,1500 (+4,05%) Börsenschluss: 04:00PM EDT

Atea Pharmaceuticals, Inc.

225 Franklin Street
Suite 2100
Boston, MA 02110
United States
857 284 8891
https://ateapharma.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 75

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Jean-Pierre Sommadossi Ph.D.	Founder, Chairman, CEO & President	1,04M	N/A	1956
Ms. Andrea J. Corcoran J.D.	CFO, Executive VP of Legal & Secretary	712,48k	N/A	1962
Mr. Keith Pietropaolo	Senior Vice President of Clinical Sciences	N/A	N/A	N/A
Dr. Jayanthi Wolf Ph.D.	Executive Vice President of Regulatory Affairs	N/A	N/A	N/A
Dr. Nancy Gail Berry Agrawal Ph.D.	Executive Vice President of Preclinical Development	N/A	N/A	N/A
Ms. Qi Huang	Senior Vice President of Virology	N/A	N/A	N/A
Ms. Kerry Gagnon	VP & Head of Quality	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Corporate Governance

Atea Pharmaceuticals, Inc.s ISS Governance QualityScore, Stand 29. April 2024, lautet 9. Die grundlegenden Scores sind Audit: 3, Vorstand: 10, Shareholderrechte: 8, Kompensation: 9.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.